Skip to main content
. Author manuscript; available in PMC: 2014 Nov 23.
Published in final edited form as: Cancer Cell. 2014 Jan 13;25(1):91–101. doi: 10.1016/j.ccr.2013.12.015

Figure 4. Heterogeneity composition determines the response to targeted therapy.

Figure 4

(A) The BRAF WT MM cell lines OPM2 (NRAS and KRAS WT, FGFR3 K650E), MM1S (KRAS G12A), SKMM1 (NRAS G12D) and the BRAF-mutant MM cell line U266 (BRAF K601N) were treated with the BRAF-inhibitor PLX4720 at the indicated concentrations. Phosphorylated and total MEK and ERK were detected by western blot at the indicated timepoints. (B) The indicated cell lines were cultured for 5 days in the absence or presence of increasing concentrations of the BRAF-inhibitor dabrafenib. Cell numbers were determined by flow cytometry on day 5 of culture and normalized to the cell number at a dabrafenib concentration of 0 µM (=100%). Error bars represent standard deviation. (C) The indicated MM cell lines were cultured in the presence of the MEK-inhibitor trametinib with or without dabrafenib at varying doses. The cell number on day 5 of culture was determined by cell titer glo. Curves with darker shades of grey represent higher concentrations of dabrafenib.